Ingredient or product comparison
Best Peptides for Anti-Aging: Clinical Comparison
BPC-157 VEGF/FGF receptor upregulation, angiogenesis acceleration Tissue repair, gut-brain axis, inflammatory modulation 250–500 mcg daily (SC or oral) Moderate. Strong preclinical data, limited human RCTs Best evidence for localized tissue repair and tendinop
This source-based comparison does not add ratings or recommend a winner.
- BPC-157
- VEGF/FGF receptor upregulation, angiogenesis acceleration
- Tissue repair, gut-brain axis, inflammatory modulation
- 250–500 mcg daily (SC or oral)
- Moderate. Strong preclinical data, limited human RCTs
- Best evidence for localized tissue repair and tendinopathy; oral bioavailability makes it unique among repair peptides
- GHK-Cu
- MMP downregulation, TIMP upregulation, lysyl oxidase cofactor
- Collagen synthesis, extracellular matrix remodeling
- 0.05–0.1% topical or 1–2 mg SC 2–3×/week
- Moderate. Multiple dermatology RCTs for skin aging
- Strong mechanistic rationale and human evidence for dermal aging; copper ion is functionally critical, not decorative
- TB-500 (Thymosin Beta-4)
- Actin polymerization, cell migration, anti-inflammatory signaling
- Wound healing, tissue regeneration, immune modulation
- 2–5 mg SC 2×/week
- Moderate. Veterinary use extensive, human trials limited
- Synergistic with BPC-157 for musculoskeletal repair; evidence strongest in acute injury contexts rather than chronic aging
- Epithalon
- Proposed telomerase activation, pineal gland regulation
- Telomere maintenance, circadian rhythm, melatonin production
- 5–10 mg SC for 10–20 days per cycle
- Weak. Russian gerontology research, minimal Western replication
- Mechanistic appeal is high, but human longevity data is largely absent; consider experimental rather than established
- MOTS-c
- AMPK activation, mitochondrial-nuclear retrograde signaling
- Metabolic health, insulin sensitivity, exercise capacity
- 5–15 mg SC 2–3×/week
- Emerging. Strong preclinical data, early-stage human trials
- Addresses metabolic aging at the mitochondrial level; particularly relevant for patients with insulin resistance or sarcopenia
- Semaglutide (GLP-1)
- GLP-1 receptor agonism, appetite suppression, insulin sensitivity
- Metabolic dysfunction, cardiovascular risk, weight management
- 0.25–2.4 mg SC weekly (titrated)
- Strong. Multiple Phase III RCTs, FDA-approved for obesity
- Not a 'longevity' peptide by design, but metabolic health is foundational to healthy aging; consider for patients with BMI >27 or metabolic syndrome